Additionally, FABP1 was considered an early biomarker that determines the extent of fatty liver infiltration in NAFLD patients through increasing steatosis and subsequent activation of the hepatic stellate cells [41]. Here, FABP1 is linked to metabolic dysfunction-associated steatotic liver disease.